China-based CARsgen Therapeutics Holdings Ltd (HKG: 2171) has announced that it has received approval from the National Medical Products Administration (NMPA) to conduct a clinical study for its chimeric antigen receptor (CAR)-T therapy, CT011. The study will focus on patients with GPC3 positive stage IIIa hepatocellular carcinoma (HCC) who are at risk of recurrence following surgical resection.
CT011, an autologous CAR-T cell therapy targeting glypican 3, had previously initiated a Phase I clinical study in China for the treatment of GPC3 positive solid tumors. This new clinical study represents a further step in expanding the application of CT011 to address a specific group of HCC patients with unmet medical needs.- Flcube.com
